NCT01565655已完成2 期
A Phase 2b, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Dose-Finding, Multi-Center Study to Evaluate the Safety and Efficacy of ASP015K in Moderate to Severe Rheumatoid Arthritis Patients
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 289
- 试验地点
- 38
- 主要终点
- Percentage of subjects achieving American College of Rheumatology Criteria 20 (ACR 20) response
研究概览
简要总结
The purpose of this study is to evaluate the safety and efficacy of ASP015K in moderate to severe rheumatoid arthritis (RA) subjects
详细描述
Subjects will take ASP015K or matching placebo orally with food for 12 weeks after randomization. Potential subjects who have previously used disease-modifying antirheumatic drugs (DMARDs) and/or biologic agents may be eligible to participate after completing a washout period. Subjects who complete the 12-week dosing period in this study may be eligible to participate in a long-term, open-label Extension Study.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Care Provider, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •≥ 6 tender/painful joints; ≥ 6 swollen joints
- •C-Reactive Protein (CRP) of ≥ 0.8 mg/dL or Erythrocyte Sedimentation Rate (ESR) of ≥ 28 mm/hr
- •Subject meets the ACR 1991 Revised Criteria for Global Functional Status in RA Class I, II or III at Screening and Baseline
- •Use of non-steroidal anti-inflammatory drugs [NSAIDs], cyclooxygenase-2 (COX-2) inhibitors, or oral corticosteroids for the treatment of RA must be stable for at least 28 days prior to start of the study
- •Male and female subjects must be willing to comply with contraception requirements as well as restrictions regarding egg and sperm donation
- •Female subject must not be breastfeeding at Screening or during the study period, and for 60 days after the final study drug administration
- •Subject agrees not to participate in another interventional study while on treatment
排除标准
- •Positive Mycobacterium tuberculosis (TB) test within 90 days of Screening
- •Abnormal chest x-ray indicative of an acute or chronic infectious process or malignancy
- •Receipt of live or live attenuated virus vaccination within 30 days prior to the first dose of study drug
- •Known history of positive test for hepatitis B surface antigen (HBsAg) or hepatitis C antibody or history of a positive test for human immunodeficiency virus (HIV) infection
- •History of any other autoimmune rheumatic disease, other than Sjogren's syndrome
- •Previous history of clinically significant infections or illness (requiring hospitalization or requiring parenteral therapy) within 90 days of the Baseline visit, or a history of any illness that would preclude participation in the study
- •History of any malignancy, except for successfully treated basal or squamous cell carcinoma of the skin or in-situ carcinoma of the cervix.
- •Does not meet specified washout criteria for the following RA medications: gold, azathioprine, minocycline, penicillamine, etanercept, certolizumab, adalimumab, golimumab, infliximab, cyclophosphamide, and leflunomide
- •Previous intolerance to Janus kinase (JAK) inhibitors
- •Receipt of intra-articular or parenteral corticosteroid within 28 days prior to the first dose of study drug or is currently taking > 30 mg oral morphine (or narcotic equivalent) per day
- •Receipt of plasma exchange therapy within 60 days prior to the start of study drug
- •Receipt of any investigational agent within 30 days or 5 half-lives, whichever is longer, prior to first dose of study drug
- •Receipt of medications that are CYP3A substrates with narrow therapeutic range within 14 days prior to first dose of study drug
- •History of heart failure, defined as New York Heart Association (NYHA) grade 3 or greater
- •History of long QT syndrome or prolonged QT interval
- •Any ongoing severe, progressive, or uncontrolled renal, hepatic, hematological, gastrointestinal, metabolic, endocrine, pulmonary, cardiac, neurological, or infectious disease, or any ongoing illness which would make the subject unsuitable for the study
- •Subject has any condition possibly affecting oral absorption (e.g., gastrectomy, other malabsorption syndromes, or clinically significant diabetic gastroenteropathy)
研究组 & 干预措施
ASP015K lowest dose
Experimental
ASP015K lowest dose once daily
干预措施: peficitinib (Drug)
ASP015K low dose
Experimental
ASP015K low dose once daily
干预措施: peficitinib (Drug)
ASP015K medium dose
Experimental
ASP015K medium dose once daily
干预措施: peficitinib (Drug)
ASP015K high dose
Experimental
ASP015K high dose once daily
干预措施: peficitinib (Drug)
Placebo
Placebo Comparator
Matching placebo once daily
干预措施: Placebo (Drug)
结局指标
主要结局
Percentage of subjects achieving American College of Rheumatology Criteria 20 (ACR 20) response
时间窗: Week 12
Trough plasma concentration of ASP015K and metabolite(s)
时间窗: up to Week 12 (6 time points)
次要结局
- Change from baseline in Disease Activity Score using 28 joint count and C Reactive Protein (DAS28-CRP)(Baseline and Week 12)
- Percentage of subjects achieving ACR 50 response(Week 12)
- Percentage of subjects achieving ACR 70 response(Week 12)
研究者
研究点 (38)
Loading locations...
相似试验
已完成
2 期
A Study to Evaluate the Safety and Efficacy of ASP015K in Moderate to Severe Rheumatoid Arthritis Subjects Who Have Had an Inadequate Response to MethotrexateArthritis, RheumatoidNCT01554696Astellas Pharma Inc379
已完成
2 期
A Study to Evaluate the Long-term Safety and Efficacy of ASP015K in Subjects Previously Enrolled in a Phase 2 ASP015K Rheumatoid Arthritis StudyArthritis, RheumatoidNCT01711814Astellas Pharma Global Development, Inc.611
已完成
2 期
A Study to Evaluate the Efficacy and Safety of ASP015K in Moderate to Severe Rheumatoid Arthritis SubjectsArthritis, RheumatoidNCT01649999Astellas Pharma Inc281
已完成
3 期
A Study to Evaluate Efficacy and Safety of ASP015K in Patients With Rheumatoid Arthritis (RA) Who Had an Inadequate Response to Methotrexate (MTX) TreatmentRheumatoid ArthritisNCT02305849Astellas Pharma Inc519
已完成
1 期
A Study to Assess the Safety, Tolerability and Pharmacokinetics of ASP015KHealthy SubjectsPharmacokinetics of ASP015KPharmacodynamicsNCT01364974Astellas Pharma Inc48